Globally, mental health-related issues are a growing concern. Pregnant women with mental health-related illnesses present a unique challenge to health professionals. During pregnancy, the decision to withhold, modify or continue psychotropic medication requires consideration of both maternal and infant outcomes. Health professionals must be aware withdrawal of these medications during pregnancy can often lead to symptom relapse. Decisions around medication management during pregnancy can be challenging due to the lack of data and occasionally conflicting data regarding safety. It is essential that women do not receive conflicting information from health professionals because this can lead to confusion and both intentional and unintentional non-adherence. Recently, it has been suggested that pharmacists may help optimise medication management and patient outcomes in perinatal care. This review outlines the use of psychotropic medications in pregnancy and discusses key considerations for those involved in providing clinical care to pregnant women with mental illness.
MENTAL HEALTH DURING PREGNANCY
Mental health problems are one of the main contributors to the overall burden of disease worldwide. 1 In 2014-15 there were 4 million Australians (17.5%) who reported having a mental or behavioural disorder. 2 According to the World Health Organization (WHO), approximately 10% of pregnant women and 13% of women worldwide who have just given birth experience a mental disorder. The WHO also states that in developing countries this rate is even higher, estimated to be 15.6% during pregnancy and 19.8% after child birth. 3 During pregnancy, untreated or poorly controlled mental illness has been linked to an increased risk of maternal and neonatal adverse outcomes, including low birth weight, preterm birth, birth defects and fetal distress. 4, 5 In many cases, adverse outcomes appear to be the result of negative lifestyle and behavioural factors commonly associated with mental illness (e.g. poor diet, cigarette smoking), necessitating the need to consider more than just mental health status alone.
Many studies focus on perinatal depression, which is prevalent worldwide and poses a significant disease burden. 6 However, there are other mental health problems that cause a significant amount of morbidity and mortality during pregnancy, including anxiety, eating disorders, psychotic disorders and alcohol and illicit drug misuse. 7 Non-pharmacological interventions are always preferable during pregnancy, but pharmacological involvement is often indicated for the management of many conditions or when other treatment options are ineffective. 7 The effects of many psychotropic medications on immediate and long-term outcomes in infants remain unclear. 7 Absent or conflicting evidence often generates safety concerns, which ultimately results in patient and healthcare provider hesitancy in the use of medications during pregnancy. 8, 9 However, the risks and benefits of medication use in pregnant women must be examined on an individual basis. Consideration should be given to the increased risk of severe episodes of mental illness associated with the perinatal period, with the immediate postpartum period carrying a very high risk for some women. It is common for people with a mental health disorder to cope with their symptoms by smoking, using alcohol or taking drugs. Strong associations have been made between unplanned pregnancy and a variety of health-related factors, including smoking, illicit drug use and depression. 10, 11 Therefore, women with a mental health disorder may be at a greater risk of unplanned pregnancy, and it is interesting to note that the incidence of unintended pregnancy in New Zealand and Australia, although difficult to establish, is estimated to be as high as 40%-50%.
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PREGNANCY AND PSYCHOTROPIC MEDICATIONS Antidepressants
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressant medication during pregnancy. 14 There is no strong evidence that the use of SSRIs as a class is associated with an increased risk of major congenital malformations. 15 Notably, any increased risk of infant malformation linked with medication use must be interpreted in the context of the background rate of 2%-4% in the general population.
Paroxetine is an exception, and has been linked to an increased risk of congenital heart defects. 16 Concerns have been raised previously about the association of low birth weight in infants exposed to antidepressants, but evidence is limited. 17 In addition, studies have been unable to establish the extent that these effects are due to antidepressants, because depression itself has been linked to low birth weight. 5 A recent study has indicated a small increased risk of preterm birth during first trimester exposure to antidepressants, but no increased risk of small for gestational age, autism spectrum disorder or attention deficit hyperactivity disorder.
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In utero exposure to SSRIs may result in neonatal abstinence syndrome (NAS) in up to 30% of infants. 19 Symptoms may occur within 48-72 h after delivery and include increased irritability, agitation, tachypnoea, poor feeding and, rarely, seizures. Most cases are generally mild and self-limiting. 20 Selective noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and benzodiazepines can also be associated with NAS. 20, 21 The controversies surrounding the association of SSRI use and persistent pulmonary hypertension of the newborn (PPHN) has been evident since the US Food and Administration (FDA) issued a public health advisory in 2006. 22 However, the FDA revised their advice in 2011 after the publication of several conflicting studies, finding insufficient evidence to conclude that SSRI use in pregnancy causes PPHN. 22 A large US study involving 128 950 women who had used an antidepressant during the 90 days before delivery (of whom 102 179 had used an SSRI and 26 771 had used a non-SSRI antidepressant) observed an increased risk of PPHN, but the absolute risk was small. 23 The authors of that study recommend the need to balance the potential but small increased risk of PPHN along with other attributed risks of SSRI use during pregnancy with the benefits that these drugs potentially have in improving maternal health and wellbeing. A 2016 systematic review and meta-analysis identified that non-serotonergic and serotonergic antidepressants were both associated with an increased risk of postpartum haemorrhage (PPH). 24 However, results are conflicting, because recent studies have identified an increased risk of PPH with the use of other psychopharmacological medications, suggesting that underlying maternal disease or factors commonly associated with mental health illness could confound the previous association. 25 Regardless of the true cause, women taking antidepressants at the time of delivery should be considered at risk of PPH and managed appropriately in this context. TCAs are much less commonly prescribed during pregnancy than SSRIs. Consequently, data on adverse infant outcomes is lacking, but overall TCAs are not associated with major congenital anomalies. 26 Clomipramine is the exception; there is a possible association with cardiovascular malformations and the drug is best avoided if possible during the first trimester of pregnancy. 27 There has been a single study suggesting a possible link between mirtazapine and respiratory problems and hypoglycaemia in the infant. 28 To date, there have been no reports of mirtazapine causing major malformations. 28 Little information is currently available regarding the safety of some of the newer antidepressants, such as agomelatine and vortioxetine. Cessation of antidepressants in pregnant women can cause exacerbation of maternal depressive symptoms and worsen both maternal and infant outcomes. In severe, recurrent depression, and in those with a history of relapse when medications are discontinued, consideration should be made to continue antidepressant treatment during pregnancy even if such patients are asymptomatic or minimally symptomatic when they conceive. 29 In addition, owing to pharmacokinetic pregnancy-related changes, there may need to be an increase in antidepressant dosage to maintain a therapeutic effect. 30 
Mood Stabilisers
In the general population the prevalence of bipolar disorder is approximately 2% and that of schizophrenia is approximately 1%, but the actual incidence during pregnancy is unknown. 31 Sodium valproate has been identified as causing teratogenic effects such as spina bifida, atrial septal defect, cleft palate and hypospadias. 32 In February 2018, the European Medicines Agency's experts in medicines safety, the Pharmacovigilance Risk Assessment Committee (PRAC), recommended that for the management of epilepsy in female patients from the time they become able to have children, valproate must not be used unless the conditions of the new pregnancy prevention program are met. 33 These measures include pregnancy testing before starting and during treatment as needed, counselling on the risks of valproate treatment and an explanation of the need for effective contraception throughout treatment. The PRAC also acknowledge that although valproate should not be used during pregnancy, for some women with epilepsy it may not be possible to stop valproate and treatment may have to be continued (with appropriate specialist care) during pregnancy. 33 Most guidelines and resources outline the safety risks associated with other mood stabilisers, such as carbamazepine and lithium, indicating the potential teratogenic effects. 34, 35 Fetal exposure to lithium during the first trimester has been shown to increase the risk of cardiac malformations. 36 A recent study in 2017 identified an increased risk of cardiac malformations, amounting to two additional cases per 100 births among pregnancies in women exposed to lithium, indicating a significantly smaller association than previously suggested. 37 The Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines suggest that in pregnant women with severe bipolar disorder, lithium may be the safest option among available mood stabilisers, providing use is balanced against the potential risks for the developing fetus and the risk of relapse during pregnancy if lithium is discontinued. 36 Data regarding the safety of newer agents, such as lamotrigine, are still emerging. Preliminary results investigating lamotrigine as monotherapy appear encouraging and the drug seems not to increase the risk of congenital defects. 38, 39 However, dose changes were necessary in some women and further studies are needed to establish overall risk.
Antipsychotics
First-generation antipsychotics such as haloperidol, chlorpromazine and prochlorperazine have demonstrated minimal risk of major congenital malformations. 40 In a recent review of the safety of second-generation antipsychotic medications, in utero exposure to aripiprazole, olanzapine and quetiapine appeared not to be associated with an increased risk of major congenital malformations. 41 A small increased risk was observed with risperidone and paliperidone. 41 Information is limited on the safety of clozapine in pregnancy. Olanzapine has been associated with an increased risk of large-for-gestationalage infants owing to the potential for metabolic side effects. 42 There is an increased risk of developing gestational diabetes in patients taking antipsychotics during early pregnancy, and therefore close glucose monitoring is recommended. 43 Third-trimester exposure to risperidone has resulted in extrapyramidal symptoms in the infant. 44 The Australian National Register of Antipsychotic Medication in Pregnancy was established in 2005 to follow-up women and infant outcomes up to a year after birth. As of April 2012, 147 pregnancies had been followed through to completion. Initial results indicate a trend towards increasing risk of preterm birth with increasing dose of antipsychotic medication. 45 Further, a total of 43% of infants required admission to an intensive or special care nursery. 45 However, overall safety appears positive, with no appreciable increase in major congenital malformations reported. During the immediate postpartum period, the risk of relapse appears to be quite high in patients with mood disorders. It is estimated that the relapse rate for women with pre-existing bipolar disorder could be as high as 50% in the first 3 weeks postpartum. 36, 46 The risk of preterm birth and fetal distress appears to be increased in women with mood disorders independent of medication exposure. 4, 5 As such, it remains unclear to what degree antipsychotic medication alone affects the short-and long-term infant outcomes in this population. There is a need for long-term follow-up and robust longitudinal studies to address these issues.
Other Psychotropics
Other medications seen in the management of mental illness include anxiolytics such as benzodiazepines. The effect of untreated anxiety and insomnia during pregnancy and the postpartum period can be significant. A systematic review has indicated that self-reported poor sleep during pregnancy is associated with an increased risk of postpartum depression. 47 Benzodiazepine use during pregnancy has been associated with low birth weight, but overall risk appears to be minimal to the infant, with no major risk of congenital anomalies. 48 If taken close to delivery, benzodiazepines can increase the risk of neonatal respiratory depression. 49 Data are lacking regarding long-term risks to children, but this should not be the sole reason to withhold treatment if symptoms are affecting maternal well-being. 50 
Alcohol, Tobacco and Illicit Drug Use
The use of alcohol, tobacco and illicit drugs during pregnancy is a common source of pregnancy-related morbidity in women and their infants. 3, 51 The reported rate of illicit drug use in Australian pregnant women varies greatly from 2.5% to 8% and may be grossly underestimated owing to self-reporting. 52 Cannabis was reported as the most common illicit drug, with the use of amphetamines, ecstasy and heroin being lower. 52 Infants born to mothers who smoke tobacco during pregnancy are more likely to be born preterm and have a low birth weight. 53 In Australia, rates of smoking in pregnancy are declining as women become increasingly aware of potential fetal harms. However, smoking cessation can be challenging, and it is estimated 6.6% of Australian women continue to smoke during pregnancy. 54 A recent review has published a summary of current international guidelines for the use of nicotine replacement therapy (NRT) during pregnancy and recommends initiation of NRT in women who are motivated to quit smoking but have been unsuccessful without medication. 55 Recommendations include using the lowest possible dose that is effective, but to use as much as needed to prevent cravings. Improving clinicians' confidence in prescribing NRT is required, as well as research to inform on the most efficacious and safest products to use during pregnancy. 55 Bupropion and varenicline should not generally be prescribed during pregnancy. Alcohol is a known teratogen, causing fetal alcohol syndrome (FAS) if consumed in excess. 56 FAS is characterised by growth retardation, characteristic facial features and impaired neurodevelopment. Significant evidence is available to demonstrate the benefit of methadone and buprenorphine treatment during pregnancy, and these drugs should be offered to those dependent on opioids as part of an integrated management program. 57 There appears to be little difference in the effects on short-term neonatal outcomes between the two agents, although some studies suggest buprenorphine is associated with reduced severity of neonatal abstinence syndrome.
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THE PHARMACIST'S ROLE
Pharmacists are ideally suited to provide input into the care of pregnant women with mental health conditions. They can act as a resource for patients and prescribers owing to their ability to research the potential teratogenic risks of medications during pregnancy. 60 Tools are being developed and becoming available to assist health professionals, including pharmacists, in the care of pregnant women with mental health conditions. 61 The tools highlight patients who have a mental health condition, including depression, mood disorders or anxiety, as well as those who smoke tobacco and use alcohol and illicit substances as a high priority for pharmacist review. A pilot randomised controlled trial of interest currently underway is investigating a patient decision aid (PDA) for antidepressant use in pregnancy. The PDA aims to help women: (1) understand why an antidepressant is being recommended; (2) be knowledgeable about the potential benefits and risks of treatment and non-treatment with antidepressants; and (3) be clear about which benefits and risks are most important to them (with the goal of improving confidence in women's decision making).
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It has been highlighted that there is a need for more accurate and current information about the safety of medications during pregnancy to enable healthcare providers to better inform patients. 63 Moreover, product information is often conservative about medication safety in pregnancy, emphasising the need to use more specialised resources. 64 Women have reported receiving conflicting information from a variety of resources, including health professionals, about medication use in pregnancy. 64 This can lead to confusion and both intentional and unintentional non-adherence to necessary medications. Table 1 identifies some key resources that pharmacists and other healthcare professionals may find useful when making recommendations or providing advice in the management of mental health disorders in the perinatal period. As medication experts, pharmacists have the opportunity to specialise in perinatal care to ensure the quality use of medication and optimal patient outcomes. There is significant potential for the role of the pharmacist to expand into the outpatient setting and for them to work as part of a multidisciplinary team, to input into the medication management of patients from preconception and throughout pregnancy.
CONCLUSION
Mental health-related issues are a growing concern globally, and pregnant women with mental healthrelated illnesses present a unique challenge to healthcare professionals to provide optimal care during this time. Medication is commonly used to control symptoms of mental illness, and it has been demonstrated that withholding or withdrawal of psychotropic medications during pregnancy in women with a mental illness can be detrimental to both maternal and infant outcomes. The specialist pharmacist is ideally placed to provide input into the care of pregnant women with mental illness due to their expertise in medication management. 51 British Association for Psychopharmacology consensus guidance on the use of psychotropic medication before, during and after pregnancy.
